The investigation and management of severe hyperandrogenism pre- and postmenopause: Non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin

References

• Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003; 101: 995–1007
   PubMed Web of Science ®Google Scholar
• Clayton R N, Ogden V, Hodgkinson J, Worswick L, Rodin D A, Dyer S, Meade T W. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?. Clin Endocrinol (Oxf) 1992; 37: 127–134
   PubMed Web of Science ®Google Scholar
• Cunningham S K, Loughlin T, Culliton M, McKenna T J. Plasma sex hormone-binding globulin and androgen levels in the management of hirsute patients. Acta Endocrinol 1983; 104: 365–371
   PubMedGoogle Scholar
• Carmina E, Rosato F, Janni A, Rizzo M, Longo R A. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91: 2–6
   PubMed Web of Science ®Google Scholar
• Barnes R B. Diagnosis and therapy of hyperandrogenism. Baillieres Clin Obstet Gynaecol 1997; 11: 369–396
   PubMedGoogle Scholar
• O'Driscoll J B, Mamtora H, Higginson J, Pollock A, Kane J, Anderson D C. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 1994; 41: 231–236
   PubMed Web of Science ®Google Scholar
• Adashi E. The climacteric ovary is a functional gonadotropin driven androgen-producing gland. Fertil Steril 1994; 62: 20–27
   PubMed Web of Science ®Google Scholar
• Fogle R H, Stanczyk F Z, Zhang X, Paulson R. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 3040–3043
   PubMed Web of Science ®Google Scholar
• Barth J H, Jenkins M, Belchetz P E. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. Clin Endocrinol (Oxf) 1997; 46: 129–130
   PubMed Web of Science ®Google Scholar
• Kaltsas G A, Isidori A M, Kola B P, Skelly R H, Chew S L, Jenkins P J, Monson J P, Grossman A B, Besser G M. The value of the low dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab 2003; 88: 2634–2643
   PubMed Web of Science ®Google Scholar
• Derksen J, Nagesser S K, Meinders A E, Haak H R, van de Velde C J. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994; 331: 968–973
   PubMed Web of Science ®Google Scholar
• Balen A H, Conway G S, Kaltsas G, Techatrasak K, Manning P J, West C, Jacobs H S. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10: 2107–2111
   PubMed Web of Science ®Google Scholar
• Hussain S, Belledregun A, Seltzer S E, Richie J P, Gittes R F, Abrams H L. Differentiation of malignant from benign adrenal masses: predictive indices on computed tomography. Am J Roentgenol 1985; 144: 61–65
   PubMedGoogle Scholar
• Kaltsas G A, Mukherjee J J, Kola B, Isidori A M, Hanson J A, Dacie J E, Reznek R, Monson J P, Grossman A B. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women?. Clin Endocrinol (Oxf) 2003; 59: 34–43
   PubMed Web of Science ®Google Scholar
• Picón J M, Lara J I, Sarasa J L, Recasens J D, Clouet R, Gonzalo M A, Rovira A. Use of a long-acting gonadotropin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour. Eur J Endocrinol 2000; 142: 619–622
   PubMedGoogle Scholar
• Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139–146
   PubMed Web of Science ®Google Scholar
• Nestler J E, Jakubowicz D J. Decreases in ovarian cytochrome P450c17 α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617–623
   PubMed Web of Science ®Google Scholar
• Nestler J E, Jakubowicz D J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 α activity and serum androgens. J Clin Endocrinol Metab 1997; 82: 4075–4079
   PubMed Web of Science ®Google Scholar
• Kowalska I, Kinalski M, Straczkowski M, Wolczyski S, Kinalska I. Insulin, leptin, IGF-I and insulin dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol 2001; 144: 509–515
   PubMed Web of Science ®Google Scholar
• Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. J Endocrinol Metab 1999; 51: 231–236
   Google Scholar
• Jakubowicz D J, Seppala M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, Koistinen R, Nestler J E. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 1126–1133
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni G E, Filicori M, Morselli-Labate A M. Effect of long term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767–2774
   PubMed Web of Science ®Google Scholar
• Harbourne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or anti-androgen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4116–4123
   PubMedGoogle Scholar
• Ng E H, Wat N M, Ho P C. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double blinded placebo controlled trial. Hum Reprod 2001; 16: 1625–1631
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. World Health Organization, Geneva 1999
   Google Scholar
• Vermeulen A, Verdonck L, Kaufman J M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672
   PubMed Web of Science ®Google Scholar
• Golden S H, Ding J, Szklo M, Schmidt M I, Duncan B B, Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol 2004; 160: 540–548
   PubMed Web of Science ®Google Scholar
• Essah P A, Nestler J E. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006; 29: 270–280
   PubMed Web of Science ®Google Scholar